ReviewTherapeutic delivery2021
An overview of vaccine development for COVID-19.
Review in Therapeutic delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy individuals: A systematic review and meta-analysis.Transplant immunology · 2022Pooled it
- Artificial intelligence in biology and medicine.Die Naturwissenschaften · 2025Review
- Vaccine Beliefs Among Uninsured People Receiving Care at Free Clinics.Journal of community health · 2025Article
- Evaluating the Protective Role of Intranasally Administered Avian-Derived IgY Against SARS-CoV-2 in Syrian Hamster Models.Vaccines · 2024Article
- Review
- Bell's Palsy, an Adverse Event Following COVID Vaccines.Iranian journal of otorhinolaryngology · 2024Review
- Article
- Uptake of COVID-19 vaccine among high-risk urban populations in Southern Thailand using the COM-B model.PloS one · 2024Article
- Health service factors affecting the COVID-19 vaccination campaign in a Ghanaian metropolis: A qualitative exploratory study.BMJ open · 2023Article
- Biomimetic SARS-CoV-2 Spike Protein Nanoparticles.Biomacromolecules · 2023Article
- A Scoping Review of the Impact of COVID-19 on Kidney Transplant Patients in the United States.Cureus · 2023Article
- Management and Characteristics of Embolism and Thrombosis After COVID-19 Vaccination: Scoping Review.Journal of multidisciplinary healthcare · 2023Article
- Article
- Comprehensive Highlights of the Universal Efforts towards the Development of COVID-19 Vaccine.Vaccines · 2022Review
- Virology and Molecular Pathogenesis of Coronavirus Disease 2019: An Update.The Eurasian journal of medicine · 2022Article
- Recent advances in the vaccine development for the prophylaxis of SARS Covid-19.International immunopharmacology · 2022Review
- Safety of COVID-19 Vaccines: Spotlight on Neurological Complications.Life (Basel, Switzerland) · 2022Review
- COVID-19 in Southeast Asia: current status and perspectives.Bioengineered · 2022Review
- The factors that affect members' use of a beauty industry matchmaking platform: Validation of the COM-B extended model.Frontiers in psychology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.